
These three studies highlight important considerations in targeting novel molecules in chronic progressive diseases such as idiopathic pulmonary fibrosis. First, it is important to recognize that every mammalian molecule is likely to have a physiological function and that complete suppression of that function will have an adverse consequence, so a detailed understanding of the pharmacokinetics of the drug is crucial before developing the definitive trial. Similarly, having a reliable pharmacodynamic biomarker to determine target engagement and the extent of drug inhibition will be vital. Finally, different methods of targeting the same molecule may have different therapeutic and adverse effects.
Like
Save
Share